Exploring Novel Parasite Ligands as Vaccine Antigens to Target the Plasmodium Life Cycle

Shan Khan^*
*Correspondence: Shan Khan, Department of Epidemiology, Mahidol University, Bangkok, Thailand, Email:

Keywords

Parasite ligands • Vaccine • Plasmodium

Introduction

Malaria, a life-threatening disease caused by Plasmodium parasites, remains a significant global health challenge, particularly in tropical and subtropical regions. Despite extensive efforts to control the disease, the development of an effective malaria vaccine has been elusive. However, recent advances in understanding parasite biology and host-pathogen interactions have identified promising targets for vaccine development. This article explores the potential of novel parasite ligands as vaccine antigens to target the complex life cycle of Plasmodium parasites [1].

Literature Review

Plasmodium parasites have a complex life cycle involving multiple stages in both human hosts and mosquito vectors. The parasite undergoes distinct developmental transitions, each presenting unique opportunities for intervention. The major stages of the Plasmodium life cycle include sporozoites, which are injected into the human host during a mosquito bite and infect hepatocytes; merozoites, which emerge from infected hepatocytes and invade red blood cells and sexual stages (gametocytes), which are taken up by mosquitoes during a blood meal, completing the transmission cycle. Parasite ligands are proteins expressed on the surface of Plasmodium parasites that mediate interactions with host cells and tissues. These ligands play crucial roles in host cell invasion, immune evasion, and disease pathogenesis, making them attractive targets for vaccine development. By targeting parasite ligands, vaccines aim to induce immune responses that prevent parasite invasion, block transmission, or eliminate infected cells [2].

AMA1 is a conserved protein essential for merozoite invasion of RBCs. Antibodies targeting AMA1 can inhibit invasion, making it a promising vaccine candidate. Recent studies have focused on designing AMA1-based vaccines with improved immunogenicity and efficacy. CSP is expressed on the surface of sporozoites and plays a critical role in hepatocyte invasion. RTS,S, a leading malaria vaccine candidate, targets CSP and has shown partial efficacy in clinical trials. Efforts are underway to enhance the efficacy of CSP-based vaccines through novel adjuvants and delivery platforms. TRAP is involved in sporozoite motility and invasion of hepatocytes. Vaccines targeting TRAP have shown promising results in preclinical studies, highlighting its potential as a vaccine antigen against the liver stage of infection. RON2 is a key component of the moving junction complex formed during merozoite invasion of RBCs. Vaccines targeting RON2 have demonstrated efficacy in animal models and are being evaluated for their potential to block blood stage infection [3].

Discussion

The circumsporozoite protein is a key surface protein expressed by Plasmodium parasites, the causative agents of malaria. This protein plays a critical role in the life cycle of the parasite, particularly during the preerythrocytic stage, where it is involved in the invasion of host hepatocytes. CSP has garnered significant attention as a potential target for malaria vaccine development due to its essential role in parasite infectivity and its accessibility to the host immune system. CSP is a large protein characterized by a conserved central region known as the central repeat region, flanked by non-repetitive N-terminal and C-terminal domains. The central repeat region consists of a tandem repeat sequence rich in asparagine, alanine, and proline residues, known as the NANP repeat. This repetitive region is highly immunogenic and is targeted by host immune responses during natural infection. CSP functions primarily during the sporozoite stage of the Plasmodium life cycle. Sporozoites are the infective form of the parasite transmitted to humans through the bite of an infected mosquito. Upon entering the bloodstream, sporozoites navigate to the liver, where they invade hepatocytes to initiate liver stage infection [4]. CSP mediates this invasion process by binding to specific receptors on the surface of hepatocytes, facilitating parasite entry into the host cell. Given its crucial role in hepatocyte invasion, CSP has been a focal point in the development of malaria vaccines. The most advanced CSP-based vaccine candidate is RTS,S/AS01, which consists of the central repeat region of CSP fused to a hepatitis B surface antigen and formulated with adjuvants. RTS,S/AS01 has shown partial efficacy in clinical trials, providing protection against malaria infection and disease in children and infants in endemic regions. The mechanism of action of RTS,S/AS01 involves the induction of antibodies targeting the central repeat region of CSP. These antibodies can interfere with sporozoite invasion of hepatocytes, thereby preventing the establishment of liver stage infection and subsequent blood stage disease. Additionally, RTS,S/AS01 induces cellular immune responses, including CD4+ T cells and CD8+ T cells, which may contribute to protection against malaria infection. Continued research efforts aimed at refining vaccine formulations, addressing challenges, and advancing our understanding of host-parasite interactions will be essential for the development of effective malaria vaccines capable of reducing the global burden of this devastating disease [5,6].

Conclusion

The identification of novel parasite ligands as vaccine antigens offers exciting prospects for malaria vaccine development. By targeting critical stages of the Plasmodium life cycle, these vaccines have the potential to prevent infection, reduce disease transmission, and contribute to malaria elimination efforts. Continued research into the immunogenicity, efficacy, and safety of novel vaccine candidates is essential for advancing malaria vaccine development and ultimately achieving the goal of malaria eradication.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Kebaier, Chahnaz, Tatiana Voza and Jerome Vanderberg. "Kinetics of mosquito-injected Plasmodium sporozoites in mice: Fewer sporozoites are injected into sporozoite-immunized mice."PLoS Pathog 5 (2009): e1000399.

   Google Scholar, Crossref, Indexed at

2. Jauréguiberry, Stéphane, Marc Thellier, Papa Alioune Ndour and Flavie Ader, et al. "Delayed-onset hemolytic anemia in patients with travel-associated severe malaria treated with artesunate, France, 2011â??2013."Emerg Infect Dis21 (2015): 804.
3. Duffy, Patrick E. and J. Patrick Gorres. "Malaria vaccines since 2000: Progress, priorities, products."npj Vaccines5 (2020): 48.

   Google Scholar, Crossref, Indexed at

4. Tadesse, Fitsum G., Lisette Meerstein-Kessel, Bronner P. Gonçalves and Chris Drakeley, et al. "Gametocyte sex ratio: The key to understanding Plasmodium falciparum transmission?."Trends Parasitol 35 (2019): 226-238.

   Google Scholar, Crossref, Indexed at

5. Ghosh, Anil K., Isabelle Coppens, Henrik GÃ¥rdsvoll and Michael Ploug, et al. "Plasmodium ookinetes coopt mammalian plasminogen to invade the mosquito midgut."Proc Natl Acad Sci108 (2011): 17153-17158.

   Google Scholar, Indexed at

6. Bacaër, Nicolas and M. Gabriela M. Gomes. "On the final size of epidemics with seasonality Bull Math Biol 71 (2009): 1954-1966.

   Google Scholar, Crossref, Indexed at